Boron neutron capture therapy in clinical application:Progress and prospect

Xu, Jing; Wang, Junjie; Wei, Qichun

doi:10.1360/tb-2021-0907

Cited by 6 publications

(8 citation statements)

References 53 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…112 The high LET properties of BNCT can be harnessed to activate immune responses and further enhance the immune response by maintaining lymphocytes in an activated state, enabling the combination of BNCT and immunotherapy. 14 This synergistic combination could significantly improve treatment outcomes and overcome the limitations of the two therapies. Further research efforts will be beneficial to further understand the mechanisms underlying the interaction between BNCT and immunotherapy and ultimately facilitate the clinical application of this combined treatment.…”

Section: Combination With Immunotherapymentioning

confidence: 99%

“…12 Fourthly, it can be applied to various types of tumors, 13 especially, the deep penetration of neutrons makes it suitable for treating deep-seated tumors. 14 Finally, it demonstrates the potential to effectively target multiple tumor deposits, making it applicable in complex treatment environments. 8 Therefore, BNCT has long been regarded as an ideal approach for treating various types of cancer, offering extensive prospects for future applications.…”

Section: Introductionmentioning

confidence: 99%

“…Currently, there are more than 20 accelerators worldwide that have been constructed or planned for BNCT. 16 Japan's first dedicated accelerator for BNCT and the boron-containing drug BPA (trade name Steboronine) 14 was officially approved for clinical application recently, marking a new stage of development for BNCT. As the technology continues to develop, BNCT will likely become a more widely available and effective cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

“…, Nle14 ] Bn (6−14) (sBB2L) as a specific agonist for gastrin-releasing h i b i t e d . peptide receptors (GRPR, BB2) overexpressed in tumor cells.…”

mentioning

confidence: 99%

See 3 more Smart Citations

The Dawn of a New Era: Tumor-Targeting Boron Agents for Neutron Capture Therapy

Luo,

Huang,

Chu

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Cancer is widely recognized as one of the most devastating diseases, necessitating the development of intelligent diagnostic techniques, targeted treatments, and early prognosis evaluation to ensure effective and personalized therapy. Conventional treatments, unfortunately, suffer from limitations and an increased risk of severe complications. In light of these challenges, boron neutron capture therapy (BNCT) has emerged as a promising approach for cancer treatment with unprecedented precision to selectively eliminate tumor cells. The distinctive and promising characteristics of BNCT hold the potential to revolutionize the field of oncology. However, the clinical application and advancement of BNCT technology face significant hindrance due to the inherent flaws and limited availability of current clinical drugs, which pose substantial obstacles to the practical implementation and continued progress of BNCT. Consequently, there is an urgent need to develop efficient boron agents with higher boron content and specific tumor-targeting properties. Researchers aim to address this need by integrating tumor-targeting strategies with BNCT, with the ultimate goal of establishing BNCT as an effective, readily available, and cutting-edge treatment modality for cancer. This review delves into the recent advancements in integrating tumor-targeting strategies with BNCT, focusing on the progress made in developing boron agents specifically designed for BNCT. By exploring the current state of BNCT and emphasizing the prospects of tumor-targeting boron agents, this review provides a comprehensive overview of the advancements in BNCT and highlights its potential as a transformative treatment option for cancer.

show abstract

Section: Combination With Immunotherapymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…, Nle14 ] Bn (6−14) (sBB2L) as a specific agonist for gastrin-releasing h i b i t e d . peptide receptors (GRPR, BB2) overexpressed in tumor cells.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The Dawn of a New Era: Tumor-Targeting Boron Agents for Neutron Capture Therapy

Luo,

Huang,

Chu

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Unlike other types of radiation therapy, BNCT uses cell-level short-range alpha particles for precise tumor killing. So far, there have been more than 2000 cases of clinical application of BNCT worldwide [ 1 ]. The potential of BNCT use in various disease sites, such as breast and prostate cancer, and the improved efficacy of many novel boron delivery agents are currently being extensively investigated in preclinical settings.…”

Section: Introductionmentioning

confidence: 99%

Boron Neutron Capture Therapy: Clinical Application and Research Progress

Cheng

Liu³

2022

Current Oncology

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a binary modality that is used to treat a variety of malignancies, using neutrons to irradiate boron-10 (10B) nuclei that have entered tumor cells to produce highly linear energy transfer (LET) alpha particles and recoil 7Li nuclei (10B [n, α] 7Li). Therefore, the most important part in BNCT is to selectively deliver a large number of 10B to tumor cells and only a small amount to normal tissue. So far, BNCT has been used in more than 2000 cases worldwide, and the efficacy of BNCT in the treatment of head and neck cancer, malignant meningioma, melanoma and hepatocellular carcinoma has been confirmed. We collected and collated clinical studies of second-generation boron delivery agents. The combination of different drugs, the mode of administration, and the combination of multiple treatments have an important impact on patient survival. We summarized the critical issues that must be addressed, with the hope that the next generation of boron delivery agents will overcome these challenges.

show abstract